Scilex Holding Co

Scilex Holding Company (Nasdaq: SCLX) is a specialty pharmaceutical company focused on non-opioid pain management, with its lead commercial product ZTlido — a lidocaine topical system approved for postherpetic neuralgia — anchoring its portfolio. The company went public through a de-SPAC merger with Vickers Vantage Corp. I, a blank-check vehicle sponsored by Vickers Capital Group that completed its IPO in 2021. At the time of this 10-Q filing, dated May 16, 2022, the de-SPAC transaction was pending, situating Scilex within the healthcare and specialty pharmaceuticals sector. The company had previously operated as a subsidiary of Sorrento Therapeutics prior to pursuing its public market path. For complete filing histories, deal analytics, and SPAC market intelligence on Scilex and hundreds of other transactions, sign up for full data on SpacDesk.